On this page
What it is
An early synthetic hexapeptide growth-hormone secretagogue.
How it is proposed to work
GHS receptor agonism — the same receptor ghrelin acts on. Appetite stimulation follows from that mechanism and is reported in animal work, but has not been measured in a human trial of GHRP-6 itself. Human studies do show it raising cortisol and prolactin alongside growth hormone.
Approved medical uses
None. GHRP-6 has no approved human medical indication in the jurisdictions we track. Any use is outside an approved label.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Human open-label2000
Combined GHRH plus GHRP-6 provocation testing for GH deficiency
Finding. A multicentre diagnostic study in 125 adults with organic pituitary disease and 125 healthy individuals, all given GHRH together with GHRP-6 intravenously. The combined test separated growth-hormone-deficient patients from controls more sharply than the insulin tolerance test did, caused no side effects, and produced peaks unaffected by age, sex, amount of adipose tissue or the assay system used. The authors proposed a diagnostic cut-off from ROC analysis.
Limitation. This is GHRH combined with GHRP-6, not GHRP-6 alone, so it cannot isolate what GHRP-6 does by itself. It is a single-administration provocation test used to classify patients, not a course of treatment, and its endpoint is a growth-hormone peak rather than body composition, function or any clinical outcome. The abstract prints the two groups separately and no combined total, so no single participant figure is recorded here. Nothing in this study addresses appetite.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
No preclinical studies catalogued.
Potential safety concerns
- CautionPreclinical
Appetite stimulation. Expected from ghrelin-receptor agonism and reported in animal work, and a predictable obstacle for anyone using it during energy restriction — but the human food-intake measurements at this receptor were made with GHRP-2, not GHRP-6. Treat the magnitude as unmeasured for this compound.
- CautionInsufficient
Cortisol and prolactin elevation, with no long-term human dataset.
Known interactions and contraindication considerations
- Not characterised in humans outside short studies.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Unapproved / investigational as of 1 Jun 2026 | No marketing authorisation. Sold as research material, which is not an approval of any kind. |
European Union EMA | Unapproved / investigational as of 1 Jun 2026 | No marketing authorisation. |
India CDSCO | Unapproved / investigational as of 1 Jun 2026 | A first-time synthetically manufactured peptide falls under the new-drug pathway. Central Licensing Authority permission is required before import or manufacture for sale or distribution. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
Appetite stimulation during a bulking phase
What is run
Used deliberately for hunger during a surplus, which is a more honest description of what it does reliably than the growth-hormone framing.
Their mechanistic reasoning
That strong ghrelin-mimetic action makes eating in a large surplus easier, with the growth-hormone pulse as a secondary benefit.
Reported in the community’s own terms. Not our position.
Stacked with
- A GHRH analogue—For the growth-hormone component.
Regimen shape
- Dose
- figure withheld
- Scale
- Microgram-scale
- Route
- Subcutaneous injection
- Frequency
- Before meals during a surplus phase
- Timing
- Fasted, shortly before eating
- Duration
- Limited to the surplus phase
Our read
Unusually, the community here is using the compound for the effect it actually wants rather than the one it is marketed on, and the mechanism supports them: GHS-receptor agonism is ghrelin's own pathway and appetite stimulation is reported in animal work. What we cannot say is that this is GHRP-6's best-characterised effect in humans. The human food-intake measurements at this receptor were made with GHRP-2, and we could locate no human GHRP-6 trial measuring appetite — a correction to what this page previously said. So the reasoning is mechanistically sound and matches what users report, but it is not backed by human data on this compound, and the open questions stand: whether pharmacologically induced hunger is a problem worth solving, and whether the cortisol and prolactin cost is acceptable for it.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
Used narrowly and knowingly, mostly by people who want the hunger. The community is unusually honest that this is what it does best, which is more than can be said for how it is marketed.
Commonly reported as helping
- Pronounced hunger, described as reliable and rapid
- Helpful for people struggling to eat in a large surplus
Also reported, when it goes wrong
- Hunger described as excessive or difficult to control
- Water retention
- Completely unusable during a fat-loss phase, widely acknowledged
Why these reports can mislead
The appetite effect is acute and obvious, so reports of it are probably accurate — an effect a user feels within the hour is one of the few things self-report handles well. What does not follow is that the trial data people cite alongside it belongs to this compound: the human food-intake measurements at this receptor were made with GHRP-2, not GHRP-6, and no human GHRP-6 trial measuring appetite could be located. Community experience and published human evidence are not agreeing here; only one of them is present. Reports of muscle gain are a different matter again — those come from people simultaneously eating substantially more, which is sufficient on its own to explain the result.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- Completely counterproductive during any fat-loss phase.
- Cortisol and prolactin elevation, unmeasured in almost all recreational use.
Active clinical trials
No registered trials currently tracked for GHRP-6.
What remains unknown
The questions that would change our assessment if they were answered.
- Does GHRP-6 itself increase food intake in humans, or has that been carried across from GHRP-2 and from animal work?
- Is there any body-composition benefit, and would an appetite effect offset it?
- Does the growth-hormone response attenuate with continued use?
References
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Dossier created.
Corrected a compound conflation. The appetite evidence this dossier relied on was generated with GHRP-2, not GHRP-6 — searches of the human GHRP-6 literature returned diagnostic provocation testing, pharmacokinetics and ACTH/cortisol work, and no trial measuring appetite, hunger or food intake. Several records that appear in an appetite search are for [D-Lys3]-GHRP-6, which is the receptor antagonist rather than this compound. The human research slot is now cited to GHRH plus GHRP-6 provocation testing, which is what the literature actually contains, and the appetite safety signal is regraded from preliminary to preclinical. Recorded rather than quietly amended, because attributing one compound's clinical data to another is the failure this platform exists to call out.
Spotted something wrong? Tell us — we publish corrections.